A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3105-3117

  Fabian, Carol J ^a   Kimler, Bruce F ^a   Brady, Deborah A ^a   Mayo, Matthew S ^a   Chang, C H Joseph ^a   Ferraro, John A ^a   Zalles, Carola M ^b   Stanton, Annette L ^c   Masood, Shahla ^d   Grizzle, William E ^e   Boyd, Norman F ^f   Arneson, Dora W ^g   Johnson, Karen A ^h  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Hutchinson Hospital   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g MIDWEST RESEARCH INSTITUTE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLACEBO; POLYAMINE; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SPERMIDINE; SPERMINE;

ADULT; ARTICLE; ASPIRATION BIOPSY; AUDIOMETRY; BLOOD ANALYSIS; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL TOXICITY; HEARING LOSS; HUMAN; IMAGING; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TINNITUS; URINALYSIS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; EFLORNITHINE; ENZYME INHIBITORS; FEMALE; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; POLYAMINES; PROLIFERATING CELL NUCLEAR ANTIGEN; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036794934     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Fisher, B., Costantino, J. P., Wickerham, D. L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
2. Verma, A. K. The enzyme-activated irreversible inhibitor of ornithine decarboxylase, DL-α-difluoromethylornithine: a chemopreventive agent. Prev. Med., 18: 646-652, 1989.
3. Glikman, P., Manni, A., Demers, L., and Bartholomew, M. Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res., 49: 1371-1376, 1989.
4. Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C., Peer, C., Wang, Y., and Sporn, M. B. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res., 61: 8412-8415. 2001.
5. Hobbs, C. A., Paul, B. A., and Gilmour, S. K. Deregulation of polyamine biosynthesis alters intrinsic histone acetyltransferase and deacetylase activities in murine skin and tumors. Cancer Res., 62: 67-74, 2002.
6. Marton, L. J., and Pegg, A. E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol., 35: 55-91, 1995.
7. Thompson, H. J., and Ronan, A. M. Effect of D, L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 7: 2003-2006, 1986.
8. Ratko, T. A., Detrisac, C. J., Rao, K. V., Thomas, C. F., Kelloff, G. J., and Moon, R. C. Interspecies analysis of the chemopreventive efficacy of dietary α-difluoromethylornithine. Anticancer Res., 10: 67-72, 1990.
9. Green, J. E., Shibata, M. A., Shibata, E., Moon, R. C., Anver, M. R., Kelloff, G., and Lubet, R. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res., 61: 7449-7455, 2001.
10. Meyskens, F. L., Gemer, E. W., Emerson, S., Pelot, D., Durbin, T., Doyle, K., and Lagerberg, W. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J. Natl. Cancer Inst. (Bethesda), 90: 1212-1218, 1998.
11. Meyskens, F. L., and Gerner, E. W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res., 5: 945-951, 1999.
12. Pegg, A. E., and Hu, R. H. Effect of polyamine analogues and inhibition of polyamine oxidase on spermidine/spermine N1-acetyltransferase activity and cell proliferation. Cancer Lett., 95: 247-252, 1995.
13. Love, R. R., Jacoby, R., Newton, M. A., Tutsch, K. D., Simon, K., Pomplun, M., and Verma, A. K. A randomized, placebo-controlled trial of low-dose α-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol. Biomark. Prev., 7: 989-992, 1998.
14. Creaven, P. J., Pendyala, L., and Petrelli, N. J. Evaluation of α-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol. Biomark. Prev., 2: 243-247, 1993.
15. Loprinzi, C. L., Messing, E. M., O'Fallon, J. R., Poon, M. A., Love, R. R., Quella, S. K., Trump, D. L., Morton, R. F., and Novotny, P. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 5: 371-374, 1996.
16. Wang, J. Y., McCormack, S. A., Viar, M. J., Wang, H., Tzen, C. Y., Scott, R. E., and Johnson, L. R. Decreased expression of protooncogenes c-fos, c-myc, and c-jun following polyamine depletion in IEC-6 cells. Am. J. Physiol., 265: G331-G338, 1993.
17. Bryans, M., Harley, E., and Gilmour, S. K. Elevated cellular polyamine levels enhance promoter activity in vivo. Biochem. Biophys. Res. Commun., 226: 618-625, 1996.
18. Kubota, S., Kiyosawa, H., Nomura, Y., et al. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J. Natl. Cancer Inst. (Bethesda), 89: 567-571, 1997.
19. Auvinen, M. Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines? J. Natl. Cancer Inst. (Bethesda), 89: 533-537, 1997.
20. Auvinen, M., Paasinen, A., Andersson, L. C., and Holtta, E. Ornithine decarboxylase activity is critical for cell transformation. Nature (Lond.), 360: 355-358, 1992.
21. Shah, N., Thomas, T. J., Lewis, J. S., Klinge, C. M., Shirahata, A., Gelinas, C., and Thomas, T. Regulation of estrogenic and nuclear factor KB functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene. 20: 1715-1729, 2001.
22. Pollard, K. J., Samuels, M. L., Crowley, K. A., Hansen, J. C., and Peterson, C. L. Functional interaction between GCN5 and polyamines: a new role for core histone acetylation. EMBO J., 18: 5622-5633, 1999.
23. Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., and Evans, R. M. Role of CBP/P300 in nuclear receptor signalling. Nature (Lond.), 383: 99-103, 1996.
24. Schiltz, R. L., Mizzen, C. A., Vassilev, A., Cook, R. G., Allis, C. D., and Nakatani, Y. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J. Biol. Chem., 274: 1189-1192, 1999.
25. Bannister, A. J., and Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature (Lond.), 384: 641-643, 1996.
26. Glikman, P. L., Manni, A., Bartholomew, M., and Demers, L. Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J. Steroid Biochem. Mol. Biol., 37: 1-10, 1990.
27. Bello-Fernandez, C., Packham, G., and Cleveland, J. L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA, 90: 7804-7808, 1993.
28. Huber, M., and Poulin, R. Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth. J. Clin. Endocrinol. Metab., 81: 113-123, 1996.
29. Moshier, J. A., Malecka-Panas, E., Geng, H., Dosescu, J., Tureaud, J., Skunca, M., and Majumdar, A. P. Ornithine decarboxylase transformation of NIH/3T3 cells is mediated by altered epidermal growth factor receptor activity. Cancer Res., 55: 5358-5365, 1995.
30. Auvinen, M., Paasinen-Sohns, A., Hirai, H., Andersson, L. C., and Holtta, E. Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS. Mol. Cell. Biol., 15: 6513-6525, 1995.
31. DisPasquale, A., White, D., and McGuire J. Epidermal growth factor stimulates putrescine transport and ornithine decarboxylase activity in cultivated human fibroblasts. Exp. Cell Res., 116: 317-323, 1978.
32. Seiler, N., Delcros, J. G., and Moulinoux, J. P. Polyamine transport in mammalian cells. An update. Int. J. Biochem. Cell Biol., 28: 843-861, 1996.
33. Leveque, J., Foucher, F., Bansard, J. Y., Havouis, R., Grall, J. Y., and Moulinoux, J. P. Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res. Treat., 60: 99-105, 2000.
34. Chanda, R., and Ganguly, A. K. Polyamines in relation to human breast, rectal and squamous cell carcinoma. Cancer Lett., 39: 311-318, 1988.
35. Persson, I., Adami, H. O., Bergkvist, L., Lindgren, A., Pettersson, B., Hoover, R., and Schairer, C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br. Med. J., 298: 147-151, 1989.
36. Manni, A., Astrow, S. H., Gammon, S., Thompson, J., Mauger, D., and Washington, S. Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res. Treat., 67: 147-156, 2001.
37. Janne, J., Poso, H., and Raina, A. Polyamines in rapid growth and cancer. Biochim. Biophys. Acta, 473: 241-293, 1978.
38. Glikman, P., Vegh, I., Pollina, M. A., Mosto, A. H., and Levy, C. M. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer (Phila.), 60: 2237-2243, 1987.
39. Manni, A., Mauger, D., Gimotty, P., and Badger, B. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin. Cancer Res., 2: 1901-1906, 1996.
40. Manni, A., Grove, R., Kunselman, S., and Aldaz, M. Involvement of the polyamine pathway in breast cancer progression. Cancer Lett., 92: 49-57, 1995.
41. Manni, A., Trout, D., Verderame, M. F., Washington, S., Mauger, D., and Demers, L. Effect of α-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res. Treat., 68: 139-146, 2001.
42. Abeloff, M. D., Slavik, M., Luk, G. D., Griffin, C. A. Hermann, J., Blanc, O., Sjoerdsma, A., and Baylin, S. B. Phase I trial and pharmacokinetic studies of α-difluoromethylornithine: an inhibitor of polyamine biosynthesis. J. Clin. Oncol., 2: 124-130, 1984.
43. Abeloff, M. D., Rosen, S. T., Luk, G. D., Baylin, S. B., Zeltzman, M., and Sjoerdsma, A. Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat. Rep., 70: 843-845, 1986.
44. Loprinzi, C. L., and Messing, E. M. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. J. Cell. Biochem. Suppl., 161: 153-155, 1992.
45. Meyskens, F. L., Kingsley, E. M., Glattke, T., Loescher, L., and Booth, A. A Phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Investig. New Drugs, 4: 257-262, 1986.
46. Kelloff, G. J., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., Knapp, G. G., et al. Clinical development plan: 2-difluoromethylornithine (DFMO). J. Cell. Biochem. Suppl., 20: 147-165, 1994.
47. Fabian, C. J., Kimler, B. F., Zalles, C. M., Klemp, J. R., Kamel, S., Zeiger, S., and Mayo, M. S. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J. Natl. Cancer Inst. (Bethesda), 92: 1217-1227, 2000.
48. Page, D. L., and Dupont, W. D. Anatomic markers of human premalignancy and risk of breast cancer. Cancer (Phila.), 66: 1326-1335, 1990.
49. Shaaban, A. M., Sloane, J. P., West, C. R., and Foster, C. S. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-α and Ki-67 expression. Am. J. Pathol., 160: 597-604, 2002.
50. Hankinson, S. E., Willet, W. C., Manson, J. E., Colditz, G. A., Hunter, D. J., Spiegelman, D., et al. Plasma sex steroid levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. (Bethesda), 90: 1292-1299, 1998.
51. Byrne, C., Schairer, C., Wolfe, J., et al. Mammographic features and breast cancer risk: effects with time, age and menopause status. J. Natl. Cancer Inst. (Bethesda), 87: 1622-1629, 1995.
52. Byrne, C., Colditz, G. A., Willet, W. C., Speizer, F. E., Pollack, M., and Hankinson, S. E. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res., 60: 3744-3748, 2000.
53. Boyd, N. F., Lockwood, G. A., Bying, J. W., et al. Mammographic densities and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 1133-1144, 1998.
54. Baker, J. A., Komguth, P. J., and Floyd, C. E., Jr. Breast imaging reporting and data system standardized mammography lexicon: observer variability in lesion description. Am. J. Roentgenol., 166: 773-778, 1996.
55. Klemp, J., Brady, D., Kimler, B., and Fabian, C. J. Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a Phase II chemoprevention trial. Eur, J. Cancer, 36: 1209-1214, 2000.
56. Zalles, C., Kimler, B. F., Kamel, S., McKittrick, R., and Fabian, C. J. Cytologic patterns in random aspirates from women at high and low risk for breast cancer. Breast J., 1: 343-349, 1995.
57. Masood, S., Frykberg, E. R., McLellan, G. L., Scalapino, M. C., Mitchum, D. G., and Bullard, J. B. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer (Phila.), 66: 1480-1487, 1990.
58. Fabian, C. J., Kamel, S., Zalles, C. M., and Kimler, B. F. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J. Cell. Biochem. Suppl., 25: 112-122, 1996.
59. Keshgegian, A. A., and Cnaan, A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am. J. Clin. Pathol., 104: 42-49, 1995.
60. van Dierendonck, J. H., Keijzer, R., van de Velde, C. J., and Cornelisse, C. J. Clear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res., 49: 2999-3006, 1989.
61. van Dierendonck, J. H., Wijsman, J. H., Keijzer, R., van de Velde, C. J., and Comelisse, C. J. Cell-cycle-related staining patterns of antiproliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am. J. Pathol., 138: 1165-1172, 1991.
62. Tuccari, G., Rizzo, A., Muscara, M., Giuffre, G., and Barresi, G. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostaining and clinico-pathologic aspects. Pathologica (Genoa), 85: 47-55, 1993.
63. Aaltomaa, S., Lipponen, P., and Syrjanen, K. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res., 13: 533-538, 1993.
64. Gee, J. M., Douglas-Jones, A., Hepburn, P., Sharma, A. K., McClelland, R. A., Ellis, I. O., and Nicholson, R. I. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J. Pathol., 177: 285-293, 1995.
65. Yu, C. C., Dublin, E. A., Camplejohn, R. S., and Levison, D. A. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen. Anal. Cell Pathol., 9: 45-52, 1995.
66. Biesterfeld, S., Kluppel, D., Koch, R., Schneider, S., Steinhagen, G., Mihalcea, A. M., and Schroder, W. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR. J. Pathol., 185: 25-31, 1998.
67. Grizzle, W. E., Meyers, R. B., and Oelschlager, D. K. Prognostic biomarkers in breast cancer: factors affecting immunohistochemical evaluation. Breast J., 1: 243-250, 1995.
68. Poyhonen, M. J., Uusitalo, U. M., Kari, A., Takala, J. A., Alakuijala, L. A., and Eloranta, T. O. Urinary excretion of polyamines: importance of circadian rhythm, age, sex, menstrual cycle, weight, and creatinine excretion. Am. J. Clin. Nutr., 52: 746-751, 1990.
69. Shinpo, K., Fujita, K., Maruta, K., Teradaira, R., and Nagatsu, T. Comparative measurements of urinary polyamines in early morning and 24-hour urine specimens. Clin. Chim. Acta. 131: 143-148, 1983.
70. Kabra, P. M., Lee, H. K., Lubich, W. P., and Marton, L. J. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebrospinal fluid, urine and tissue. J. Chromatogr., 380: 19-32, 1986.
71. Hu, T., Zuo, H., Riley, C. M., Stobaugh, J. F., and Lunte, S. M. Determination of α-difluoromethylornithine in blood by microdialysis sampling and capillary electrophoresis with UV detection. J. Chromatogr. A., 716: 381-388, 1995.
72. Boyd, N. F., Lockwood, G. A., Marten, L. J., Knight, J. A., Jong, R. A., Fishell, E., et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J. Natl. Cancer Inst. (Bethesda), 91: 1404-1408, 1999.
73. Ware, J. E., and Sherbourne, C. D. The MOS 36-item short form health survey (SF-36). 1. Conceptual framework and item selection. Med. Care (Phila.), 30: 473-483, 1992.
74. Ware, J. E. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: Health Assessment Lab, New England Medical Center, 1993.
75. Ware, J. E. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: Health Assessment Lab, New England Medical Center, 1994.
76. Sidawy, M. K., Stoler, M. H., Frable, W. J., Frost, A. R., Masood, S., Miller, T. R., Silverberg, S. G., Sneige, N., and Wang, H. H. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Study. Diagn. Cytopathol., 18: 150-165, 1998.
77. Shotland, L. I., Ondrey, F. G., Mayo, K. A., and Viner, J. L. Recommendations for cancer prevention trials using potentially ototoxic test agents. J. Clin. Oncol., 19: 1658-1663, 2001.
78. Huber, M., and Poulin, R. Antiproliferative effect of spermine depletion by N-cyclohexyl-1,3-diaminopropane in human breast cancer cells. Cancer Res., 55: 934-943, 1995.
79. Brune, B., Hartzell, P., Nicotera, P., and Orrenius, S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp. Cell Res., 195: 323-329, 1991.
80. Mommers, E. C., van Diest, P. J., Leonhart, A. M., et al. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum. Pathol., 29: 1539-1545, 1998.
81. Mommers, E. C., van Diest, P. J., Leonhart, A. M., Meijer, C. J., and Baak, J. P. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res. Treat., 58: 163-169, 1999.
82. Kendra, K. L., and Katzenellenbogen, B. S. An evaluation of the involvement of polyamines in modulating MCF-7 human breast cancer cell proliferation and progesterone receptor levels by estrogen and antiestrogen. J. Steroid Biochem., 28: 123-128, 1987.
83. Kremmer, T., Palyi, I., Daubner, D., Boldizsar, M., Vincze, B., Paulik, E., Sugar, J., Pokorny, E., and Tury, E. Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts. Anticancer Res., 11: 1807-1813, 1991.
84. Manni, A., Badger, B., Martel, J., and Demers, L. Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice. Cancer Lett., 66: 1-9, 1992.
85. Leveque, J., Burtin, F., Catros-Quemener, V., Havouis, R., and Moulinoux, J. P. The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo. Anticancer Res., 18: 2663-2668, 1998.
86. Carbone, P. P., Pirsch, J. D., Thomas, J. P., Douglas, J. A., Verma, A. K., Larson, P. O., Snow, S., Tutsch, K. D., and Pauk, D. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol. Biomark. Prev., 10: 657-661, 2001.
87. Brenner, D. E., Normolle, D. P., Kresty, L. A., et al. Effect of difluoromethylornithine (DFMO) upon cellular proliferation and cyclin D expression in human metaplastic Barrett's esophagus mucosa. Proc. Am. Assoc. Cancer Res., 43: 1007, 2002.
88. Mitchell, M. F., Tortolero-Luna, G., Lee, J. J., Hittelman, W. N., Lotan, R., Wharton, J. T., Hong, W. K., and Nishioka, K. Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin. Cancer Res., 4: 303-310, 1998.
89. Love, R. R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplun, M., and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst. (Bethesda), 85: 732-737, 1993.
90. Osborne, C. K., Zhao, H., and Fuqua, S. A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol., 18: 3172-3186, 2000.
91. Wallon, U. M., Shassetz, L. R., Cress, A. E., Bowden, G. T., and Gerner, E. W. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol. Carcinog., 11: 138-144, 1994.
92. Boiko, I. V., Mitchell, M. F., Pandey, D. K., White, R. A., Hu, W., Malpica, A., Nishioka, K., Boone, C. W., Atkinson, E. N., and Hittelman, W. N. DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of α-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol. Biomark. Prev., 6: 849-855, 1997.
93. Urban, D., Myers, R., Manne, U., Weiss, H., Mohler, J., Perkins, D., Markiewicz, M., Lieberman, R., Kelloff, G., Marshall, M., and Grizzle, W. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur. Urol., 35: 429-438, 1999.
94. Fabian, C. J., Kimler, B. F., Elledge, R. M., Grizzle, W. E., Beenken, S. W., and Ward, J. H. Models for early chemoprevention trials in breast cancer. Hematol. Oncol. Clin. N. Am., 12: 993-1017, 1998.
95. Harper-Wynne, C., Ross, G., Sacks, N., et al. A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res. Treat., 65: 225, 2001.
96. Dooley, W. C., Ljung, B. M., Veronesi, U., et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1624-1632, 2001.
97. Wrensch, M. R., Petrakis, N. L., Miike, R., King, E. B., Chew, K., Neuhaus, J., Lee, M. M., and Rhys, M. Breast cancer risk in women with abnormal cytology in nipple aspirates of beast fluid. J. Natl. Cancer Inst. (Bethesda), 93: 1791-1798, 2001.
98. Nielsen, M., Thomsen, J. L., Primdahl, S., et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br. J. Cancer, 56: 814-819, 1987.
99. Bhathal, P. S., Brown, R. W., Lesueur, G. C., et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br. J. Cancer, 51: 271-278, 1985.
100. Schnitt, S. J., Connolly, J. L., Tavassoli, F. A., Fechner, R. E., Kempson, R. L., Gelman, R., and Page, D. L. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am. J. Surg. Pathol., 16: 1133-1143, 1992.
101. Tan-Chiu, E., Costantino, J., Wang, J., Paik, S., Bulch, C., Wickerham, D. L., and Wolmark, N. The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. Breast Cancer Res. Treat., 69: 210, 2001.
102. Final version: the uniform approach to breast fine-needle aspiration biopsy. Breast J., 3: 149-168, 1997.
103. Bacus, J. W., Boone, C. W., Bacus, J. V., Follen, M., Kelloff, G. J., Kagan, V., and Lippman, S. M. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 8: 1087-1094, 1999.
104. Makris, A., Powles, T. J., Allred, D. C., Ashley, S. E., Trott, P. A., Ormerod, M. G., Titley, J. C., and Dowsett, M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res. Treat., 53: 51-59, 1999.
105. Chang, J., Powles, T. J., Allred, D. C., Ashley, S. E., Makris, A., Gregory, R. K., Osborne, C. K., and Dowsett, M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin. Cancer Res., 6: 616-621, 2000.
106. Dowsett, M., Dixon, J. M., Horgan, K., Salter, J., Hills, M., and Harvey, E. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin. Cancer Res., 6: 2260-2267, 2000.
107. Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombart-Cussac, A., Jaenicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., and Borgs, M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol., 19: 3808-3816, 2001.
108. Allred, D. C., Mohsin, S. K., and Fuqua, S. A. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer, 8: 47-61, 2001.
109. Shrestha, P., Yamada, K., Wada, T., Maeda, S., Watatani, M., Yasutomi, M., Takagi, H., and Mori, M. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Arch. A Pathol. Anat. Histopathol., 421: 193-202, 1992.
110. Oza, A. M., and Boyd, N. F. Mammographic parenchymal pattems: a marker of breast cancer risk. Epidemiol. Rev., 15: 196-208, 1993.
111. Gertig, D. M., Stillman, I. E., Byrne, C., Spiegelman, D., Schnitt, S. J., Connolly, J. L., Colditz, G. A., and Hunter, D. J. Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiol. Biomark. Prev., 8: 873-879, 1999.
112. Ursin, G., Parisky, Y. R., Pike, M. C., and Spicer, D. V. Mammographic density changes during the menstrual cycle. Cancer Epidemiol. Biomark. Prev., 10: 141-142, 2001.
113. Boyd, N. F., Byng, J. W., Jong, R. A., Fishell, E. K., Little, L. E., Miller, A. B., Lockwood, G. A., Tritchler, D. L., and Yaffe, M. J. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J. Natl. Cancer Inst. (Bethesda), 87: 670-675, 1995.
114. White, E., Velentgas, P., Mandelson, M. T., Lehman, C. D., Elmore, J. G., Porter, P., Yasui, Y., and Taplin, S. H. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J. Natl. Cancer Inst. (Bethesda), 90: 906-910, 1998.
115. Persson, I., Thurfjell, E., and Holmberg, L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J. Clin. Oncol., 15: 3201-3207, 1997.
116. Atkinson, C., Warren, R., Bingham, S. A., et al. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol. Biomark. Prev., 8: 863-866, 1999.
117. Brisson, J., Brisson, B., Cote, G., Maunsell, E., Berube, S., and Robert, J. Tamoxifen and mammographic breast densities. Cancer Epidemiol. Biomark. Prev., 9: 911-915, 2000.
118. Pollak, M. Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer, 36: 1224-1228, 2000.
119. Bonanni, B., Johansson, H., Gandini, S., Guerrieri-Gonzaga, A., Torrisi, R., Sandri, M. T., Cazzaniga, M., Mora, S., Robertson, C., Lien, E. A., and Decensi, A. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res. Treat., 69: 21-27, 2001.
120. Decensi, A., Mariani, L., Johansson, H., et al. Role of plasma IGF-1 as a surrogate biomarker of second breast cancer in a prevention trial of fenretinide. Proc. Am. Assoc. Cancer Res., 43: 821, 2002.